# Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA）

> **NCT07127042** · PHASE2 · RECRUITING · sponsor: **ScinnoHub Pharmaceutical Co., Ltd.** · enrollment: 270 (estimated)

## Conditions studied

- Total Knee Arthroplasty

## Interventions

- **DRUG:** Low-dose BT-114143
- **DRUG:** High-dose BT-14143
- **DRUG:** Tranexamic Acid (IV)

## Key facts

- **NCT ID:** NCT07127042
- **Lead sponsor:** ScinnoHub Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07127042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07127042, "Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA）". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07127042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*